Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.

Conclusion: TFR seems achievable in patients with sustained MR4.5 after switching to nilotinib.
Primary Funding Source: Novartis Pharmaceuticals Corporation.
PMID: 29459949 [PubMed - as supplied by publisher]

Source: Annals of Internal Medicine - February 20, 2018 Category: Internal Medicine Authors: Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, Fellague-Chebra R, Acharya S, Wong S, Jin Y, Hughes TP Tags: Ann Intern Med Source Type: research